---
schema_version: "secwatch.filing_event.v1"
accession: "0001404644-26-000038"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2026-05-12T20:06:30+00:00"
generated_at: "2026-05-12T21:28:56.264434+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neurogene reports Q1 net loss $30.9M; ~90% dosed in Rett gene therapy trial, cash runway to Q1 2028

## Summary
- Net loss $30.9M for Q1 2026 vs $22.6M in Q1 2025; R&D expenses $25.2M driven by NGN-401 trial and CMC costs.
- ~90% of participants dosed in Embolden registrational trial; on track to complete dosing in Q2 2026; no HLH at 1E15 vg dose.
- Cash, equivalents and short-term investments $243.2M as of March 31, 2026; expected to fund operations through Q1 2028.
- Appointed Christy Shafer as Chief Commercial Officer; Christine Mikail added to Board of Directors.
- Interim Phase 1/2 data with ≥12 months follow-up for all 10 participants expected mid-2026.

## SEC filing metadata
- accession: 0001404644-26-000038
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2026-05-12T20:06:30+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000038/0001404644-26-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000038/ngne-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001404644-26-000038
- JSON: https://secwatch.observer/filing/0001404644-26-000038.json
- Plain text: https://secwatch.observer/filing/0001404644-26-000038.txt

## Key facts
- Earnings Releases
  Neurogene Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $30.9 million for the three months ended March 31, 2026, compared to $22.6 million for the three months end.
  - Period: the quarter ended March 31, 2026
  - Net income: Net loss was $30.9 million for the three months ended March 31, 2026, compared to $22.6 million for the three months end
  - Result: reported results
  source text: Net loss was $30.9 million for the three months ended March 31, 2026, compared to $22.6 million for the three months ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000038/0001404644-26-000038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.